NKGN vs. RVPH, BYSI, GANX, ME, FBLG, AADI, QNCX, VHAQ, CNTX, and KALA
Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Reviva Pharmaceuticals (RVPH), BeyondSpring (BYSI), Gain Therapeutics (GANX), 23andMe (ME), FibroBiologics (FBLG), Aadi Bioscience (AADI), Quince Therapeutics (QNCX), Viveon Health Acquisition (VHAQ), Context Therapeutics (CNTX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.
NKGen Biotech vs.
Reviva Pharmaceuticals (NASDAQ:RVPH) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
Reviva Pharmaceuticals has higher earnings, but lower revenue than NKGen Biotech. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Reviva Pharmaceuticals received 27 more outperform votes than NKGen Biotech when rated by MarketBeat users.
Reviva Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.
In the previous week, NKGen Biotech had 6 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 7 mentions for NKGen Biotech and 1 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.80 beat NKGen Biotech's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.
Reviva Pharmaceuticals currently has a consensus target price of $11.40, indicating a potential upside of 533.33%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than NKGen Biotech.
63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 74.7% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Reviva Pharmaceuticals beats NKGen Biotech on 9 of the 14 factors compared between the two stocks.
Get NKGen Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NKGen Biotech Competitors List
Related Companies and Tools
This page (NYSE:NKGN) was last updated on 2/17/2025 by MarketBeat.com Staff